JP5721275B2 - 治療的使用のための新規７−デアザプリンヌクレオシド - Google Patents

治療的使用のための新規７−デアザプリンヌクレオシド Download PDF

Info

Publication number
JP5721275B2
JP5721275B2 JP2012506333A JP2012506333A JP5721275B2 JP 5721275 B2 JP5721275 B2 JP 5721275B2 JP 2012506333 A JP2012506333 A JP 2012506333A JP 2012506333 A JP2012506333 A JP 2012506333A JP 5721275 B2 JP5721275 B2 JP 5721275B2
Authority
JP
Japan
Prior art keywords
compound
compound according
ddd
nmr
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012506333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524731A5 (OSRAM
JP2012524731A (ja
Inventor
アウレリー ボーデルー，
アウレリー ボーデルー，
マイケル ホセク，
マイケル ホセク，
ペトル ナウス，
ペトル ナウス，
Original Assignee
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ．
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ．, インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ． filed Critical インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ．
Publication of JP2012524731A publication Critical patent/JP2012524731A/ja
Publication of JP2012524731A5 publication Critical patent/JP2012524731A5/ja
Application granted granted Critical
Publication of JP5721275B2 publication Critical patent/JP5721275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012506333A 2009-04-22 2010-04-19 治療的使用のための新規７−デアザプリンヌクレオシド Active JP5721275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17165609P 2009-04-22 2009-04-22
US61/171,656 2009-04-22
PCT/CZ2010/000050 WO2010121576A2 (en) 2009-04-22 2010-04-19 Novel 7-deazapurine nucleosides for therapeutic uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014213410A Division JP6087889B2 (ja) 2009-04-22 2014-10-20 治療的使用のための新規７−デアザプリンヌクレオシド

Publications (3)

Publication Number Publication Date
JP2012524731A JP2012524731A (ja) 2012-10-18
JP2012524731A5 JP2012524731A5 (OSRAM) 2013-05-30
JP5721275B2 true JP5721275B2 (ja) 2015-05-20

Family

ID=42768153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012506333A Active JP5721275B2 (ja) 2009-04-22 2010-04-19 治療的使用のための新規７−デアザプリンヌクレオシド
JP2014213410A Active JP6087889B2 (ja) 2009-04-22 2014-10-20 治療的使用のための新規７−デアザプリンヌクレオシド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014213410A Active JP6087889B2 (ja) 2009-04-22 2014-10-20 治療的使用のための新規７−デアザプリンヌクレオシド

Country Status (15)

Country Link
US (3) US9321800B2 (OSRAM)
EP (1) EP2421879B1 (OSRAM)
JP (2) JP5721275B2 (OSRAM)
CN (2) CN104497084B (OSRAM)
AU (3) AU2010238985B2 (OSRAM)
CA (2) CA2759131C (OSRAM)
DK (1) DK2421879T3 (OSRAM)
ES (1) ES2437917T3 (OSRAM)
HR (1) HRP20131021T1 (OSRAM)
MX (1) MX2011011160A (OSRAM)
NZ (2) NZ596301A (OSRAM)
PL (1) PL2421879T3 (OSRAM)
PT (1) PT2421879E (OSRAM)
SI (1) SI2421879T1 (OSRAM)
WO (1) WO2010121576A2 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2759131C (en) * 2009-04-22 2017-06-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 7-deazapurine nucleosides for therapeutic uses
US20130023491A1 (en) * 2009-12-18 2013-01-24 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN102319254B (zh) * 2011-07-20 2013-06-19 上海交通大学 5-碘代杀菌核素在制备抗肿瘤药物中的应用
CZ305466B6 (cs) * 2013-11-04 2015-10-14 Ústav organické chemie a biochemie Akademie věd České republiky, v. v. i. Substituované 7-deazapurinové ribonukleosidy pro terapeutické použití
EA039885B1 (ru) 2014-11-14 2022-03-23 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3478701B1 (en) 2016-06-29 2022-08-10 Ustav organicke chemie a biochemie AV CR, v.v.i. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3697800A1 (en) 2017-10-19 2020-08-26 Universiteit Gent Nucleoside analogues for the treatment of parasitic infections
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
AU2019317549A1 (en) 2018-08-07 2021-02-25 Msd International Gmbh PRMT5 inhibitors
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
MA56544A (fr) * 2019-06-18 2022-04-27 Taiho Pharmaceutical Co Ltd Nouveau compose ester d'acide phosphorique possedant un squelette pyrolo-pyrimidine ou sel pharmaceutiquement acceptable de celui-ci
EP4106763A1 (en) * 2020-02-17 2022-12-28 Katholieke Universiteit Leuven KU Leuven Research & Development Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
KR102639275B1 (ko) * 2021-06-08 2024-02-21 퓨쳐메디신 주식회사 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물
CN118355022A (zh) 2021-09-28 2024-07-16 安特卫普大学 用于治疗寄生虫感染的核苷类似物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
SK286630B6 (sk) * 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
WO2003051899A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
CA2484921A1 (en) * 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US20040157892A1 (en) 2003-02-12 2004-08-12 Crompton Co./Cie Pesticidal fluoroethyl pyrazoles
WO2005044835A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
EP1680436A1 (en) * 2003-10-27 2006-07-19 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006033709A2 (en) * 2004-07-29 2006-03-30 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
JP5485172B2 (ja) * 2008-01-18 2014-05-07 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー， アカデミー オブ サイエンシズ オブ ザ チェコ リパブリック 新規な細胞増殖抑制性７−デアザプリンヌクレオシド
MX2010014501A (es) * 2008-06-23 2011-02-25 Janssen Pharmaceutica Nv Antagonistas de piperidil acrilamida de receptor 2 de citocina quimioatrayente.
GB0815968D0 (en) * 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
CA2759131C (en) * 2009-04-22 2017-06-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 7-deazapurine nucleosides for therapeutic uses

Also Published As

Publication number Publication date
EP2421879A2 (en) 2012-02-29
US9321800B2 (en) 2016-04-26
US10294262B2 (en) 2019-05-21
WO2010121576A2 (en) 2010-10-28
AU2015205885B2 (en) 2017-04-06
CA2759131A1 (en) 2010-10-28
CA2966647A1 (en) 2010-10-28
US20150218201A1 (en) 2015-08-06
WO2010121576A3 (en) 2011-06-16
AU2010238985B2 (en) 2015-04-23
AU2017204148A1 (en) 2017-07-06
CA2759131C (en) 2017-06-20
AU2010238985A1 (en) 2011-12-01
EP2421879B1 (en) 2013-09-04
AU2015205885A1 (en) 2015-09-03
HK1209129A1 (en) 2016-03-24
US20160318970A1 (en) 2016-11-03
HRP20131021T1 (hr) 2014-01-31
NZ596301A (en) 2014-10-31
JP2015013901A (ja) 2015-01-22
CN102459300A (zh) 2012-05-16
AU2017204148B2 (en) 2018-12-06
NZ700583A (en) 2016-04-29
DK2421879T3 (da) 2013-11-25
CN104497084A (zh) 2015-04-08
US9624257B2 (en) 2017-04-18
PT2421879E (pt) 2013-12-09
SI2421879T1 (sl) 2014-01-31
HK1166325A1 (en) 2012-12-14
ES2437917T3 (es) 2014-01-15
PL2421879T3 (pl) 2014-02-28
JP6087889B2 (ja) 2017-03-01
MX2011011160A (es) 2012-01-27
CN102459300B (zh) 2014-12-10
US20170240584A1 (en) 2017-08-24
JP2012524731A (ja) 2012-10-18
CN104497084B (zh) 2018-06-05

Similar Documents

Publication Publication Date Title
JP6087889B2 (ja) 治療的使用のための新規７−デアザプリンヌクレオシド
JP5485172B2 (ja) 新規な細胞増殖抑制性７−デアザプリンヌクレオシド
HK1166325B (en) Novel 7-deazapurine nucleosides for therapeutic uses
HK1234411A1 (en) Novel cytostatic 7-deazapurine nucleosides
HK1209129B (zh) 用於治疗用途的7-脱氮嘌呤核苷
HK1234411B (en) Novel cytostatic 7-deazapurine nucleosides
HK1149016B (en) Novel cytostatic 7-deazapurine nucleosides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150323

R150 Certificate of patent or registration of utility model

Ref document number: 5721275

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250